CRAD B.ST Stock Analysis
CR
Neutral
Based on Eyestock quantitative analysis, CRAD B.ST`s fundamental data and valuation indicate an investment grade of Neutral at the current time.
Rating
To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.
Moderate score
Upside
To determine whether the current price is a reasonable to buy a stock, we compare it to our estimate of fair value. The more undervalued a stock is, the higher the upside.
Greatly undervalued
C-RAD AB engages in the development of innovative solutions for use in advanced radiation therapy. The company is headquartered in Uppsala, Uppsala. The company went IPO on 2007-07-23. The company offers products and solutions to the radiation therapy market. C-Rad AB is the parent company within the C-Rad group (the Group). The Group provides such products, as Sentinel, a surface contour laser scanning system for patient positioning, monitoring and gating applications; Catalyst, a surface scanning system, which allows the identification and tracking of markers, and GEMini, a system based on a gaseous detector using metal converters interleaved with Gas Electron Multipliers (GEMs), as well as other products. The firm operates through several subsidiaries: C-RAD Positioning AB, C-RAD Imaging AB, C-RAD Innovation AB and Cyrpa International Sprl. The Company’s largest shareholder is Inter Life Science AB.